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Abstract
Background: In severe post-partum haemorrhage, death can occur within hours of bleeding onset so interventions
to control the bleeding must be given immediately. In clinical trials of treatments for life-threatening bleeding,
established treatments are given priority and the trial treatment is usually given last. However, enrolling patients in
whom severe maternal morbidity or death is imminent or inevitable at the time of randomisation may dilute the
effects of a trial treatment.
Methods: We conducted an exploratory analysis of data from the WOMAN trial, an international, randomised
placebo-controlled trial of the effects of tranexamic acid on death and surgical intervention in 20,060 women with
post-partum haemorrhage. We assessed the impact of early maternal death or hysterectomy due to exsanguination
on the effect of tranexamic acid on each of these respective outcomes. We conducted repeated analyses excluding
patients with these outcomes at increasing intervals from the time of randomisation. We quantified treatment
effects using risk ratios (RR) and 99% confidence intervals (CI) and prepared cumulative failure plots.
Results: Among 14,923 women randomised within 3 h of delivery (7518 tranexamic acid and 7405 placebo), there
were 216 bleeding deaths (1.5%) and 383 hysterectomies due to bleeding (2.8%). After excluding deaths from
exsanguination at increasing time intervals following randomization, there was a significant reduction in the risk of
death due to bleeding with tranexamic acid (RR = 0.41; 99% CI 0.19–0.89). However, after excluding hysterectomies
at increasing time intervals post-randomization, there was no reduction in the risk of hysterectomy due to bleeding
with tranexamic acid (RR = 0.79; 99% CI 0.33–1.86).
Conclusions: Findings from this analysis provide further evidence that tranexamic acid reduces the risk of death
from exsanguination in women who experience postpartum haemorrhage. It is uncertain whether tranexamic acid
reduces the risk of hysterectomy for bleeding after excluding early hysterectomies.
Trial registration: ISRCTN trial registration number ISRCTN76912190, 8 Dec 2008; ClinicalTrials.gov number
NCT00872469, 30 March 2009; PACTR number PACTR201007000192283, 9 Feb 2010; EudraCT number 2008–008441-
38, 8 Dec 2010 (retrospectively registered).
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Background
Tranexamic acid reduces bleeding by inhibiting the
breakdown of fibrin blood clots. When given prior to in-
cision, tranexamic acid reduces blood loss in elective
surgery by about one third [1]. The CRASH-2 trial
showed that early tranexamic acid administration re-
duces death due to bleeding in trauma patients with or
at risk of significant haemorrhage [2]. The WOMAN
trial assessed the effects of tranexamic acid on death,
hysterectomy and other outcomes in 20,060 women with
post-partum haemorrhage (PPH). There was a signifi-
cant reduction in death due to bleeding with tranexamic
acid (RR = 0·81, 95% CI 0·65–1·00; p = 0·045) [3]. As in
traumatic haemorrhage, the reduction was greatest when
treatment was given early (within 3 h of delivery), (RR
0·69, 95% CI 0·53–0·90; p = 0·007), with no apparent re-
duction after 3 h [3, 4]. There was also a decrease in
laparotomy to control bleeding in women who received
tranexamic acid (RR 0·64, 95% CI 0·49–0·85; p = 0·002).
Based on these results, the World Health Organization
has recommended the early use (within 3 h of birth) of
tranexamic acid for the treatment of PPH [5].
In the WOMAN trial, tranexamic acid did not prevent
hysterectomy due to bleeding (RR = 0.95 95%CI 0.78–
1.16, p = 0.611). During the trial, we noticed that clini-
cians sometimes decided to perform a hysterectomy at
or prior to the time of randomisation and so tranexamic
acid could not influence the decision. We predicted that
including such hysterectomies as ‘outcome measures’ in
the trial would reduce or obscure the effect of tranex-
amic acid [6].
Inappropriate assumptions about the timing of an ex-
posure’s effect can cause bias towards the null [7]. Even
when outcome events occur after randomisation, some
will be imminent or inevitable at the time of randomisa-
tion and so cannot be prevented by the trial treatment.
This is a particular problem in trials in life threatening
emergencies when the trial treatment is usually given
after the established treatments. Although a trial would
ideally evaluate a treatment as it would be used in clin-
ical practice, it is difficult to ensure that a treatment of
uncertain effectiveness is given urgently, particularly
when clinicians know that half of the patients will re-
ceive a placebo.
Given the extent of blood loss in PPH, many of the
women enrolled in the WOMAN trial were probably
critically ill at the time of randomisation: 59% of women
had haemodynamic instability. As such, hysterectomy or
death may have been imminent or inevitable in some
women. Such outcomes would likely have occurred soon
after randomisation. We hypothesised that the inclusion
of imminent or inevitable outcome events in the analysis
would dilute the treatment effect towards the null. To
estimate an undiluted measure of effect, Rothman
proposed repeated analyses with varying assumptions
about the timing of an exposure’s effect [7]. We aimed
to examine whether early outcome events diluted the ef-
fect of tranexamic acid on death due to bleeding and
hysterectomy due to bleeding by conducting repeated
analyses excluding outcomes at increasing intervals from
randomisation.
Methods
The WOMAN trial was a randomised, placebo-controlled
trial of the effect of tranexamic acid on death, hysterec-
tomy and other morbidities in women with PPH. It in-
cluded 20,060 women aged 16 years and older with a
clinical diagnosis of PPH recruited from 193 hospitals in
21 countries between 2010 and 2016. We randomly allo-
cated women to receive 1 g of tranexamic acid or placebo
by slow intravenous injection. If bleeding continued after
30 min or restarted within 24 h of the first dose, we gave a
second dose of 1 g of tranexamic acid or placebo. We ob-
tained follow-up data for 99.8% of patients. We have pub-
lished full details of the trial rationale, design, methods
and results elsewhere [3, 6].
We conducted the trial in accordance with good clin-
ical practice guidelines. The relevant ethics committees
and regulatory agencies approved the consent proce-
dures. We obtained informed consent from women if
their physical and mental capacity allowed. If a woman
could not give consent, we obtained proxy consent from
a relative or representative. If no proxy was available,
then if local regulation allowed, we deferred or waived
the consent. In these cases, we told the woman about
the trial as soon as possible and obtained consent for
use of the data collected.
Analysis
We conducted exploratory analyses of the WOMAN
trial dataset using the method proposed by Rothman [7].
Our primary outcome was death due to bleeding and
our secondary outcome was hysterectomy due to bleed-
ing. We prepared frequency bar charts of the time inter-
vals between randomisation and death due to bleeding
and between randomisation and hysterectomy due to
bleeding in the treatment and placebo groups to show
the time course of bleeding-related outcomes. We then
examined the effect of tranexamic acid on these out-
comes among women treated within 3 h of delivery
since tranexamic acid only appears to be effective when
given within this timeframe [3, 4]. We hypothesised that
maternal deaths or hysterectomies due to bleeding that
occurred soon after randomisation were imminent or in-
evitable at the time of randomisation. As such, we
assessed the impact of early deaths or hysterectomies
due to bleeding on the treatment effect by conducting
repeated analyses excluding patients with these
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outcomes at increasing intervals from randomisation.
We also excluded patients who died from any cause
within the relevant exclusion period, as they could not
contribute to the denominator. We increased the length
of the exclusion period by one hour at a time, up to 10 h
for deaths due to bleeding but 5 h for hysterectomy due
to bleeding since there were few hysterectomies beyond
5 h. We excluded hysterectomies completed before ran-
domisation. We conducted intention-to-treat and
per-protocol analyses and quantified treatment effects
using risk ratios and 99% confidence intervals. We used
99% rather than 95% confidence intervals due to the
multiple number of between-group comparisons. We
prepared plots of the cumulative percentage of death
due to bleeding and hysterectomy due to bleeding in
order to supplement the period-specific risk ratios,
which can be susceptible to selection bias [8]. We
assessed the proportional hazards assumption using the
Grambsch-Therneau global test.
To assess the risk of selection bias from
post-randomisation exclusions we examined the distri-
bution of baseline characteristics by treatment group.
We used stratified analyses to assess potential confound-
ing factors including age, time to treatment, type and
place of delivery, cause of haemorrhage, use of utero-
tonic prophylaxis, estimated blood loss, blood transfu-
sion, and second dose of the trial treatment (or placebo).
We adjusted for relevant factors using multivariable log
binomial regression and selected a final model using
likelihood ratio tests. We also conducted sensitivity ana-
lyses of women treated within an hour of delivery,
women with uterine atony as the primary cause of
haemorrhage, and women who underwent caesarean
section.
Results
In the WOMAN trial, 20,060 women were randomly
assigned to receive tranexamic acid (n = 10,051) or pla-
cebo (n = 10,009). After excluding 39 women who did
not fulfil the eligibility criteria, withdrew consent or
were lost to follow up, data on 20,021 women were
available for analysis. Ten women (< 0.1%) had missing
data on time of delivery or time of randomisation, so
time to treatment was calculated in the remaining
20,011 women. Of these, 14,923 women were rando-
mised within 3 h of delivery (7518 tranexamic acid and
7405 placebo), with a mean time from delivery to ran-
domisation of 1 h (interquartile range = 0.4–1.5 h). Data
on time of haemorrhage death were available for all
women. Data on time of hysterectomy for bleeding or
hysterectomy status were missing for 45 women (0.3%),
leaving 14,878 patients for the hysterectomy analyses.
Among women randomised within 3 h of delivery, there
were 216 deaths due to bleeding (1.5%) and 383
hysterectomies due to bleeding (2.8%). Here we present
the results of intention-to-treat analyses. In per-protocol
analyses, we excluded 19 women who did not receive
tranexamic acid (n = 9) or placebo (n = 10). The results
of the per-protocol analysis were almost identical (see
Additional file 1: Tables S1 and S2). The trial arms
remained balanced by baseline characteristics (see Add-
itional file 1: Tables S3 and S4), and there was no evi-
dence of confounding (see Additional file 1: Tables S5
and S6).
Figure 1 shows a frequency bar chart of the interval
between randomisation and death due to bleeding for
the placebo group (n = 173) and tranexamic acid group
(n = 138) over the 24 h after randomisation. The distri-
bution was positively skewed, with 42% of all deaths
from exsanguination occurring within 3 h of randomisa-
tion, 58% within 5 h, and 80% within 10 h. Thirty-five
(10%) deaths from exsanguination occurred more than
24 h after randomisation.
Table 1 shows risk ratios for death due to bleeding in
women treated within 3 h of delivery, excluding women
who died at increasing intervals from randomisation.
When all women were included, there was a 31% reduc-
tion in the risk of death due to bleeding with tranexamic
acid (RR = 0.69, 99% CI 0.48–0.98). Excluding women
who died soon after randomisation increased the treat-
ment effect. The effect was largest after excluding
women who died within 9 h of randomisation, with a
59% reduction in death due to bleeding (RR = 0.41, 99%
CI 0.19–0.89). Although there was a decreasing trend in
risk ratios, the 99% confidence intervals were wide and
overlapping. In sensitivity analyses of women treated
within an hour of delivery, women with uterine atony
and women who underwent caesarean section, we ob-
served the same decreasing trend in risk ratios (see Add-
itional file 1: Tables S7-S9).
Figure 2 shows a plot of the cumulative percentage of
deaths from bleeding by time from randomisation in the
tranexamic acid and placebo groups. For the first few
hours after randomisation the curves overlap but later
they separate. The Grambsch-Therneau test for propor-
tional hazards gave p = 0.06.
Figure 3 shows a frequency bar chart of the interval
between randomisation and hysterectomy due to bleed-
ing in the placebo group (n = 263) and tranexamic acid
group (n = 245) for the 24 h after randomisation. Again,
the distribution was positively skewed with 38% of hys-
terectomies for bleeding occurring within one hour of
randomisation and 82% within 3 h. Less than 2% of hys-
terectomies for bleeding (n = 9) occurred more than
24 h after randomisation.
Table 2 shows risk ratios for hysterectomy due to
bleeding for women treated within 3 h of delivery, ex-
cluding women who underwent hysterectomy at
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increasing intervals from randomisation. When all
women were included, there was no reduction in the risk
of hysterectomy due to bleeding with tranexamic acid
(RR = 0.95, 99% CI 0.73–1.23). Excluding women who
had a hysterectomy for bleeding soon after randomisa-
tion resulted in a decrease in the risk ratio (RR = 0.79;
99% CI 0.33–1.86), however, the 99% confidence inter-
vals overlapped the null at each exclusion interval.
Figure 4 shows a plot of the cumulative percentage of
hysterectomy for bleeding by time from randomisation
in the tranexamic acid and placebo groups. In the first
hours after randomisation the curves were similar but
with minimal separation later. The Grambsch-Therneau
test for proportional hazards gave p = 0.17.
Discussion
In the original WOMAN trial, women who experienced
PPH were randomized to receive tranexamic acid vs pla-
cebo. In the WOMAN trial, we observed a 19% reduc-
tion in the risk of death from exsanguination in women
who received tranexamic acid compared to placebo, with
a 31% reduction in women treated within 3 h of giving
birth. In this secondary analysis of WOMAN trial data,
after excluding deaths due to bleeding that occurred
soon after randomisation, we observed a lower risk of
death from exsanguination in women who received early
tranexamic acid compared to placebo (RR = 0.41; 99% CI
0.19–0.89). Some women may have been so critically ill
at the time of randomisation that death was imminent
Fig. 1 Deaths due to bleeding within 24 h of randomisation by treatment group and hours since randomisation
Table 1 Impact of early deaths due to bleeding on the effect of tranexamic acid
Exclusion interval
(hours from
randomisation)
Exclusionsa N Death due to bleeding
TXA (%) Placebo (%) TXA Placebo TXA
(%)
Placebo
(%)
Risk ratio
(99% CI)
None – – 7518 7405 89 (1.2) 127 (1.7) 0.69 (0.48–0.98)
1 14 (0.2) 15 (0.2) 7504 7390 76 (1.0) 114 (1.5) 0.66 (0.45–0.96)
2 30 (0.4) 38 (0.5) 7488 7367 61 (0.8) 92 (1.3) 0.65 (0.43–1.00)
3 42 (0.6) 57 (0.8) 7476 7348 50 (0.7) 75 (1.0) 0.66 (0.41–1.05)
4 53 (0.7) 70 (1.0) 7465 7335 42 (0.6) 64 (0.9) 0.64 (0.39–1.07)
5 62 (0.8) 77 (1.0) 7456 7328 33 (0.4) 59 (0.8) 0.55 (0.31–0.96)
6 66 (0.9) 85 (1.2) 7452 7320 29 (0.4) 53 (0.7) 0.54 (0.30–0.97)
7 73 (1.0) 94 (1.3) 7445 7311 23 (0.3) 44 (0.6) 0.51 (0.26–0.99)
8 80 (1.1) 97 (1.3) 7438 7308 18 (0.2) 41 (0.6) 0.43 (0.21–0.89)
9 83 (1.1) 101 (1.4) 7435 7304 16 (0.2) 38 (0.5) 0.41 (0.19–0.89)
10 84 (1.1) 104 (1.4) 7434 7301 16 (0.2) 37 (0.5) 0.42 (0.20–0.91)
a% is the proportion of the original trial arm excluded (N = 7518 TXA, N = 7405 placebo). TXA = tranexamic acid. Includes women treated within 3 h of
delivery only
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and inevitable regardless of treatment. The findings of
this secondary analysis extend those of the original
WOMAN trial by further highlighting the importance of
tranexamic acid as an early life-saving intervention for
women who experience PPH.
The plasma concentration of tranexamic acid
needed to inhibit fibrinolysis is around 5–15 mg/L
and tranexamic acid has a half-life of 2–3 h [9–14].
After an intravenous injection of 1 g of tranexamic
acid, the plasma concentration should exceed this
range for several hours [13, 15]. Because it is elimi-
nated by the kidneys, the concentration could remain
elevated for much longer in women with severe
bleeding and renal impairment [16]. Further research
on the pharmacokinetics and pharmacodynamics of
tranexamic acid in obstetric bleeding will help to de-
termine the optimal dosing regimen.
Our analysis has important limitations. Although the
statistical analysis plan, which we prepared before seeing
the trial results, anticipated that outcomes determined
prior to randomisation would dilute the treatment effect,
the exploratory analyses presented here were not
pre-specified and comprise multiple between-group
comparisons. The possibility of a type 1 error cannot be
excluded and so our results require cautious interpret-
ation. That said, in keeping with our hypothesis, we ob-
served an increase in the treatment effect on death due
to bleeding with an increasing exclusion interval. This
Fig. 2 Cumulative percentage of deaths due to bleeding by time from randomisation in the tranexamic acid and placebo group
Fig. 3 Hysterectomies due to bleeding within 24 h of randomisation by treatment group and hours since randomisation
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finding was consistent in several sensitivity analyses. The
temporal distribution of haemorrhage deaths allowed us
to exclude women who died soon after randomisation.
We did not observe a statistically significant decrease in
the risk of hysterectomy for bleeding associated with
tranexamic acid compared with placebo after excluding
hysterectomies performed early after randomization. Al-
though this finding suggests that tranexamic acid may
not decrease the need for hysterectomy as a life-saving
surgical intervention for PPH, it is possible that our
sample size was inadequate to show a true treatment
benefit when excluding early hysterectomies.
Period-specific risk ratios are susceptible to selection
bias [8]. Because tranexamic acid reduces deaths due to
bleeding, post-randomisation exclusions based on
time-to-outcome are not independent of treatment. In-
deed, we excluded 20 more deaths from the placebo
group than from the treatment group. Although this
might be expected to obscure rather than inflate the de-
layed effects of treatment, because we do not have data
on patient characteristics at each time point selection
bias remains a concern. Figure 2 provides some unbiased
evidence of a lack of treatment benefit early on, in line
with our hypothesis that early deaths due to bleeding
may dilute the treatment effect, but this may be a spuri-
ous finding.
The validity of our results also depend on the accuracy
of data on the time of randomisation (treatment) and
the time of death but measurement error is inevitable.
Although we urged investigators to give the trial treat-
ment as soon as possible after randomisation, some out-
comes would have occurred before the treatment was
completed. Time of death could have been misclassified
since there is often an interval between death and its
formal confirmation.
Because maternal death can occur soon after major
uncontrolled PPH, interventions to compensate for
blood loss (e.g. blood transfusion) and control the bleed-
ing (e.g. hysterectomy) may occur early after PPH diag-
nosis, often prior to administration of the trial
Table 2 Impact of early hysterectomies due to bleeding on the effect of tranexamic acid
Exclusion
interval (hours
from
randomisation)
Exclusionsa N Death due to bleeding
TXA (%) Placebo (%) TXA Placebo TXA (%) Placebo (%) Risk ratio (99% CI)
None – – 7494 7384 188 (2.5) 195 (2.6) 0.95 (0.73–1.23)
1 90 (1.2) 93 (1.3) 7404 7291 112 (1.5) 117 (1.6) 0.94 (0.67–1.32)
2 175 (2.3) 167 (2.3) 7319 7217 42 (0.6) 64 (0.9) 0.65 (0.39–1.08)
3 205 (2.7) 214 (2.9) 7289 7170 23 (0.3) 34 (0.5) 0.67 (0.33–1.33)
4 217 (2.9) 236 (3.2) 7277 7148 19 (0.3) 25 (0.4) 0.75 (0.34–1.63)
5 227 (3.0) 246 (3.3) 7267 7138 16 (0.2) 20 (0.3) 0.79 (0.33–1.86)
a% is the proportion of the original trial arm excluded (N = 7494 TXA, N = 7384 placebo). TXA = tranexamic acid. Includes women treated within 3 h of
delivery only
Fig. 4 Cumulative percentage of hysterectomies for bleeding by time from randomisation in the tranexamic acid and placebo groups
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treatment. We conjecture that this may potentially ex-
plain the lack of any effect of tranexamic acid on
blood transfusion and hysterectomy in the WOMAN
trial. However, the results for hysterectomy were in-
conclusive and we did not have data on time of
transfusion. Future studies are needed to examine the
effect of tranexamic acid on haemorrhage-related
morbidity, and should report the timing of relevant
medical and surgical interventions, such as time to
first transfusion, uterine balloon tamponade, interven-
tional radiology, and surgical intervention (including
hysterectomy and laparotomy).
Conclusions
In this secondary analysis of data from the WOMAN
trial, we observed that tranexamic acid was associated
with a reduced risk of maternal death from exsanguin-
ation after excluding early maternal deaths from the ana-
lysis. This finding is in line with the main findings from
the WOMAN trial. Our results suggest that the inclu-
sion of early deaths in the analysis may have diluted the
treatment effect of tranexamic acid towards the null.
Early outcome events could represent those that are
imminent and inevitable. Therefore, the outcomes of
some women with life-threatening PPH occurring soon
after delivery may not be influenced by exposure to the
study drug. These findings also raise the possibility that
if we give women tranexamic acid as a first line treat-
ment for PPH rather than a last resort, as now recom-
mended by the World Health Organization [5], its effect
on reducing the risk of death due to bleeding may ex-
ceed that observed in the WOMAN trial. However, these
results should be viewed with caution due to the ex-
ploratory nature of this analysis. It remains uncertain
whether tranexamic acid reduces the risk of hysterec-
tomy for bleeding after excluding early hysterectomies
post-randomisation. Further studies are needed to exam-
ine the effect of tranexamic acid on morbidity in PPH.
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delivery (Table S7); a sensitivity analysis of women with uterine atony as
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Ethical Committee; Federal Medical Centre Owo Ethical Review Commit-
tee; Federal Medical Centre, Umuahia; Federal Medical Centre, Yenagoa;
Federal Teaching Hospital Abakaliki Research Ethics Committee; Irrua
Specialist Teaching Hospital Research Ethics Committee; Jos University
teaching Hospital Institutional Health Research Ethics Committee; Kogi
State Specialist Hospital Research and Ethical Committee; Ladoke Akin-
tola University of Technology Teaching Hospital Ethical Committee;
Lagos Island Maternity Hospital Ethical Committee; Lagos State University
Teaching Hospital Health Research and Ethics Committee; Lagos Univer-
sity Teaching Hospital Research & Ethics Committee; Mother & Child
Hospital Akure Research Ethics Committee; National Hospital Abuja Ethics
Committee; Nigeria National Health Research Ethics Committee; Nnamdi
Azikiwe UTH Ethical Committee; Obafemi Awolowo University Teaching
Hospital Ethics & Research Committee; Plateau State Specialist Hospital
Health Research Ethics Committee; Seventh Day Adventist Hospital In-
ternal Review Board and Ethics Committee; University of Ibadan/Univer-
sity College Hospital Ethics Committee; University of Abuja Teaching
Hospital Health Research Ethics Committee; University of Calabar Teach-
ing Hospital Ethical Committee; University of Ilorin Teaching Hospital
Ethical Reveiw Committee; University of Maiduguri Teaching Hospital
Ethics and research Committee; University of Nigeria Hospital Research
Ethics Committee; University of Uyo teaching Hospital Institutional Re-
view Committee; Usmanu Danfodiyo University Teaching Hospital Sokoto
Ethical Research Committee; Obafemi Awolowo University Teaching Hos-
pital Ethics & Research Committee.
Pakistan: Ayub Teaching Hospital Ethical Committee; Institutional Ethical
Review Committee Bolan Medical College; Cantonment General Hospital
Rawalpindi Ethics Committee; Institutional Ethics Committee, Combined
Military Hospital Kharian; Combined Military Hospital Lahore Ethics
Committee; Rawalpindi Medical College and Allied Hospitals Research and
Ethics Committee; Fatima Bai Hospital Ethical Review Committee;
Institutional Review Board Fatima Memorial Hospital; Ethical Committee
Federal Government PolyClinic; Institutional Review Board Services Institute
of Medical Sciences; Isra University Hospital Ethical Committee; AIMC/Jinnah
Hospital Lahore Ethical Review Board; Ethical Review Committee Kahota
Research Laboratory Hospital Islamabad; Institutional Review Board King
Edward Medical University; Institutional Research & Ethics Board Lady
Reading Hospital; Institutional Review Board King Edward Medical University;
Liaquat Ethics Review Committee; Ethics Review Committee Liaquat
University Hospital; Ethics Commitee MCH PIMS; Mian Muhammad Trust
Hospital Ethics Committee; Research and Ethic Committee Islamabad
Medical Complex Nescom; Institutional Ethical Review Committee Nishtar
Medical College & Hospital Multan; Islamic International College Trust
Pakistan Railway Hospital; Ethics Committee Patel Hospital; Ethical Review
Committee People’s University of Medical and Health Sciences; Rehman
Medical Institute Peshawar Institutional Review Committee; Ethics Committee
Shalamar Hospital; Ethical Committee Sharif Medical and Dental College;
Institutional Review Board and Ethics Committee Shifa International Hospital;
Sir Ganga Ram Hospital Lahore Ethics Committee; Zainab Panjwani Memorial
Hospital Ethics Committee; Ziauddin Medical College.
Papua New Guinea: School of Medicine Research and Ethics Committee.
Sudan: National Medicines and Poisons Board.
Tanzania: Prime Ministers Office, Regional Administration and Local
Government; Muheza Designated District Hospital; Muhimbili National
Hospital; Mwananyamala Hospital; Temeke Municipal Council.
Uganda: Makerere University; Ugandan National Council of Science and
Technology.
United Kingdom: Nottingham University Hospitals NHS Trust Research &
Development Department; Liverpool Women’s NHS Foundation Trust R&D
Department; Central Manchester University Hospitals NHS Foundation Trust
R&D; Guys and St Thomas NHS Foundation Trust Research and
Development; City Hospitals Sunderland NHS Foundation Trust Research and
Development; The Newcastle Upon Tyne NHS Foundation Trust Research
and Development.
Zambia: Chipata General Hospital; Kabwe General Hospital Ethics Committee;
University of Zambia Biomedical Ethics Committee; Livingstone General
Hospital; St Paul’s Mission Hospital, Kashikishi; St Francis Hospital Research
Ethics Committee; University of Zambia Biomedical Ethics Committee.
The relevant ethics committees and regulatory agencies approved the
consent procedures at each site. We obtained informed consent from
women if their physical and mental capacity allowed. For fully competent
women, an information sheet was provided, the study was discussed and
written consent obtained. If the woman was unable to read or write then
the information sheet was read to her and she then marked the consent
form with either a cross or thumbprint. In this event, a witness not
associated with the trial provided a full signature confirming the mark. If a
woman could not give consent, we obtained proxy consent from a relative
or representative in the same manner. If no proxy was available, then if local
regulation allowed, we deferred or waived the consent. In these cases, we
told the woman about the trial as soon as possible and obtained consent for
use of the data collected. The consent procedures are described in detail in
the trial protocol.
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